Rhythm Pharmaceuticals, Inc. RYTM Return on assets
Return on assets at other companies
Other financials
Where this comes from
Calculated from Rhythm Pharmaceuticals, Inc.’s reported figures.
Based on trailing twelve months.
The official record: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rhythm Pharmaceuticals, Inc.'s return on assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rhythm Pharmaceuticals, Inc.'s return on assets?
- Rhythm Pharmaceuticals, Inc. (RYTM) reported return on assets of -48.9% in Q1 2026.
- How has Rhythm Pharmaceuticals, Inc.'s return on assets changed year-over-year?
- Rhythm Pharmaceuticals, Inc.'s return on assets increased by 6.5% year-over-year, from -52.3% to -48.9%.
- What is the long-term trend for Rhythm Pharmaceuticals, Inc.'s return on assets?
- Over 5 years (2020 to 2025), Rhythm Pharmaceuticals, Inc.'s return on assets has grown at a -3.6% compound annual growth rate (CAGR), from -54.1% to -45.1%.
- What does return on assets mean?
- Trailing-twelve-month net income divided by average total assets. Measures how efficiently the asset base generates profit, independent of how those assets are financed. Computed as net income over average total assets — note this is OpenCapital's standard definition and may differ from data vendors that use alternative numerators.